
GSK-2140944
CAS No. 1075236-89-3
GSK-2140944( Gepotidacin | GSK2140944 )
Catalog No. M10308 CAS No. 1075236-89-3
GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 328 | Get Quote |
![]() ![]() |
50MG | 1746 | Get Quote |
![]() ![]() |
100MG | 2502 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameGSK-2140944
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.
-
DescriptionGSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and MRSA; shows antibacterial activity against MSSA and MRSA isolates (MIC90=0.5 ug/ml).Bacterial Infection Phase 2 Clinical.
-
In VitroGepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism and has demonstrated in vitro activity against gram-negative and gram-positive bacterias , including drug-resistant strains, and also targets pathogens associated with other conventional and biothreat infections. The MIC50 and MIC90 for gepotidacin against the 25 N. gonorrhoeae isolates tested are 0.12 and 0.25 μg/mL, respectively. The gepotidacin MIC90s are as follows (in μg/mL): Streptococcus pyogenes, 0.25; Escherichia coli, 2; Moraxella catarrhalis, ≤0.06; Streptococcus pneumoniae, 0.25; Haemophilus influenzae, 1; Clostridium perfringens, 0.5; and Shigella spp., Gepotidacin hasin vitroactivity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs).
-
In VivoGSK2140944 MICs are 0.125 to 0.5 mg/L against the six MRSA isolates. ELF penetration ratios range from 1.1 to 1.4. Observed maximal decreases are 1.1 to 3.1 log10 CFU in neutropenic mice. The mean fAUC/MIC ratios required for stasis and 1-log-unit decreases are 59.3 ± 34.6 and 148.4 ± 83.3, respectively.
-
SynonymsGepotidacin | GSK2140944
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research AreaInfection
-
IndicationBacterial Infection
Chemical Information
-
CAS Number1075236-89-3
-
Formula Weight448.527
-
Molecular FormulaC24H28N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 7.14 mg/mL 15.92 mM
-
SMILESO=C(C=NC(C=C1)=C23)N3[C@H](CN4CCC(NCC(N=C5)=CC6=C5OCCC6)CC4)CN2C1=O
-
Chemical Name(2R)-2-[[4-[[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl]amino]-1-piperidinyl]methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bax BD, et al. Nature. 2010 Aug 19;466(7309):935-40.
2. Biedenbach DJ, et al. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23.
3. So W, et al. Antimicrob Agents Chemother. 2015 Aug;59(8):4956-61.
4. Farrell DJ, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16.
molnova catalog



related products
-
Nevadensin
Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM.
-
Azathramycin
A macrolide antibiotic that effectively inhibits tumor angiogenesis by suppressing VEGFR2-mediated signaling pathways in lung cancer.
-
Methicillin sodium
Methicillin Sodium is the sodium salt form of methicillin a semisynthetic beta-lactam penicillin antibiotic with beta-lactamase resistant activity.